Drs. Geoffrey Oxnard and Lauren Ritterhouse consider the current landscape of reimbursement for molecular biomarker testing, the need to run FDA-approved tests, and the role of CMS and local Medicare providers in testing reimbursement.
Video Library —December 18, 2018
Categories:
Interview with the InnovatorsThoracic Oncologist, Dana-Farber Cancer Institute,
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Associate Professor of Medicine, Harvard Medical School,
Boston, MA
Molecular Pathologist and Co-Director
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Molecular Diagnostics and Clinical Genomics Laboratories, University of Chicago
Chicago, IL
Last modified: August 10, 2023